-

11:15:55 PM

EXEL Stock News

EXEL - Exelixis Inc

10/19/21 4:05 PM

Nasdaq : EXEL

earnings

Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021

Exelixis, Inc. announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021 after the markets close. At 5:00 p.m. EDT/ 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Founded in 1994, Exelixis, Inc. is a commercially...

RHEA-AI

neutral

10/14/21 8:00 AM

Nasdaq, NYSE : EXEL, RDY

clinical trial

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma

Exelixis, Inc. and Aurigene Discovery Technologies Limited today announced that Exelixis has exercised its exclusive option under the companies’ July 2019 agreement to in-license XL114, a novel anti-cancer compound that inhibits the CARD11-BCL10-MALT1 signaling pathway, which promotes lymphocyte survival and proliferation. XL114 is the second...

RHEA-AI

very positive

10/14/21 8:00 AM

Nasdaq : EXEL

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Exelixis, Inc. and STORM Therapeutics today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer. Under the terms of the agreement, Exelixis will pay STORM an upfront fee of $17 million in...

RHEA-AI

positive

09/20/21 11:30 AM

Nasdaq : EXEL

clinical trial

Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021

Exelixis, Inc. today announced final results from the phase 3 COSMIC-311 pivotal trial of CABOMETYX ® in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer. Following a previous announcement that the trial met one of the two primary endpoints of significant improvement versus placebo in progression-free...

RHEA-AI

very positive

09/18/21 7:30 AM

Nasdaq : EXEL

clinical trial

Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021

Exelixis, Inc. today announced detailed results from the expanded cohort 6 of the phase 1 b COSMIC-021 trial of cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer. The data are being presented during the Proffered Paper Session: GU Tumours, Prostate today at 1:30 p.m. CEST at the 2021 European...

RHEA-AI

neutral

09/17/21 4:23 PM

Nasdaq : EXEL

fda approval

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Exelixis, Inc. today announced that the U.S. Food and Drug Administration approved CABOMETYX ® for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior vascular endothelial growth factor receptor- targeted therapy and who are...

RHEA-AI

very positive

09/16/21 2:30 AM

Nasdaq : EXEL

Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021

Exelixis, Inc. today announced results demonstrating efficacy benefits regardless of prior nephrectomy status with CABOMETYX ® in combination with Bristol Myers Squibb’ s OPDIVO ® versus sunitinib for patients with previously untreated advanced renal cell carcinoma. “Patients with advanced kidney cancer who do not have a prior nephrectomy typically...

RHEA-AI

neutral

09/06/21 1:00 PM

Nasdaq : EXEL

Exelixis Statement on the Passing of Two Senior Executives

Exelixis, Inc. today announced that Gisela M. Schwab, M.D., the company’ s President, Product Development and Medical Affairs and Chief Medical Officer, passed away over the weekend. Exelixis President and Chief Executive Officer Michael M. Morrissey, Ph.D., issued the following statement on behalf of the Exelixis team and the company’ s Board of Directors:.

RHEA-AI

positive

09/01/21 4:05 PM

Nasdaq : EXEL

conferences

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September

Exelixis, Inc. today announced that members of the company’ s management team will participate in fireside chats at the following virtual investor conferences in September:. Morgan Stanley 19 th Annual Global Healthcare Conference: Exelixis is scheduled to present at 1:15pm EDT/ 10:15am PDT on Thursday, September 9, 2021. H.C. Wainwright 23 rd Annual Global...

RHEA-AI

neutral

08/25/21 4:05 PM

Nasdaq : EXEL

Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

Exelixis, Inc. today announced Takeda Pharmaceutical Company Limited, its partner responsible for the clinical development and commercialization of CABOMETYX ® in Japan, and Ono Pharmaceutical Co., Ltd. received approval from the Japanese Ministry of Health, Labor and Welfare to manufacture and market CABOMETYX in combination with OPDIVO ® as a...

RHEA-AI

very positive

1 2 3 4 5 6 Next

EXEL Data:

IndustryResearch and Development in Biotechnology
Websitewww.exelixis.com
Security nameExelixis Inc
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code8731
Employees773
Tags
- Health Technology
- Biotechnology

EXEL Description:

Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, it established a broad drug discovery and development platform that has served as the foundation for its continued efforts to bring new cancer therapies to patients in need. Its discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and it has entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from its marketed products and collaborations, it is committed to prudently reinvesting in its business to maximize the potential of its pipeline. It is supplementing its existing therapeutic assets with targeted business development activities and internal drug discovery - all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor's (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. In November 2020, the company was named to Fortune's 100 Fastest-Growing Companies list for the first time, ranking 17th overall and the third-highest biopharmaceutical company.